PDCI Market Access is happy to be sponsoring the Canadian Institute: Pharma Symposium Canada 2015. This year’s expanded program scope reflects the critical role that timely access to drugs plays in our healthcare system. This event will bring together a greater number of stakeholders from both the public and private sectors to foster collaborative discussions that could, in turn, lead to shorter time in development for new drugs and sustainable prices for payers and manufacturers alike. For more information on the conference, including agenda, speakers and registration information, please click here to download the official brochure.
As a sponsor, we will be at our exhibit booth giving demonstrations of our Canadian Drug Claims Database, handing out custom reports, answering questions regarding our services and featuring our all new C-MAP™ Canadian Drug Benefit Plans Reference Guide 15th Anniversary Edition. Furthermore, PDCI will be opening Day 2 with a presentation on ‘Canada’s Global Ranking: Drug Pricing, Reimbursement and Market Access.’
Topics covered include:
- The global environment currently faced by manufacturers, and emerging trends
- To what extent does pricing from public or private payers in other markets impact pricing in Canada?
- What are the global trends related to product listing agreements (PLA) and how do they compare to Canadian PLA negotiations?
- How do other markets recognize therapeutic innovation compared to Canada?
- What impact is CETA expected to have on the Canadian pricing and reimbursement landscape?
Finally, PDCI has arranged a special discount for our clients and colleagues to save $200 off the cost of the registration. To redeem your savings, mention priority code 276BX10 when you register!
Top Reasons to attend:
- Keep current on the PMPRB, PCPA and CADTH and how their activities will impact your organization
- Gain insights on what forces are driving manufacturers decisions and those of public and private payers now and into the future
- Hear why a change in business models may be needed to bring orphan and specialty drugs to market
- Gain essential insights and information into industry developments for market and strategy development
- Develop valuable contacts for future collaboration
Successful CDR, pCODR & INESSS Submissions -CANCELLED
Due to a lack of registrants, the pre-conference workshop has been cancelled. For those who may still be interested in the workshop, PDCI is more than happy to provide the workshop in the form of a Webinar or in-house training. Please contact Andrew Brooke for more information on how to register.
High quality HTA submissions to CDR, pCODR, INESSS are a critical factor for the successful launch of innovative new drugs and biologics. This workshop will be led by senior staff from PDCI Market Access including those with many years of experience preparing HTA submissions (over 60) across a wide range of therapeutic areas and recent experience working at the CDR who will provide unique insights into the CADTH review process.
Participants at this interactive workshop will walk away with knowledge to:
- Better understand the CDR/pCODR/INESSS processes, requirements and timelines
- Gain insights into the internal CDR review processes: what reviewers like and dislike
- Understand the impact of patient input, how it is processed and how it is valued by expert committees
- Learn how to anticipate and address objections to the clinical evidence and cost effectiveness models
- Recognize and address internal / corporate obstacles and the limitations of using Global Value Dossiers
- Gain an understanding of differences and unique requirements of pCODR and INESSS
- Learn how to make the most of pre- and post-submission meetings
- Understand how to adapt public HTA submissions to private payers taking into account the unique perspectives and needs of private payers
- Understand the impact of the public HTA submissions on subsequent PCPA negotiations
Develop successful HTA submission strategies through this interactive workshop